Thermo Fisher Scientific Inc. with ticker code (TMO) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $670.00 and $553.00 and has a mean share price target at $624.92. (at the time of writing). Now with the previous closing price of $536.87 and the analysts are correct then we can expect a percentage increase in value of 16.4%. Also worth taking note is the 50 day moving average now sits at $569.31 and the 200 day MA is $538.15. The market cap for the company is 207.15B. The stock price is currently at: $542.69 USD
The potential market cap would be $241,127,912,312 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 34.83, revenue per share of $110.37 and a 4.82% return on assets.
Thermo Fisher Scientific Inc. is engaged in serving science. The Company operates through four segments. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. Analytical Instruments segment provides an offering of instruments and the supporting consumables, software and services that are used for a range of applications. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
